# Vaccine Therapy in Treating Patients With Metastatic Melanoma

> **NCT00087373** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 28 (actual)

## Conditions studied

- Recurrent Melanoma
- Stage IV Melanoma

## Interventions

- **BIOLOGICAL:** recombinant fowlpox-TRICOM vaccine
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00087373
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-06
- **Primary completion:** 2006-02
- **Final completion:** —
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2014-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00087373

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00087373, "Vaccine Therapy in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00087373. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*